Methylphenidate News and Research

RSS

Pfizer completes acquisition of NextWave Pharmaceuticals

Pfizer Inc. today announced that it has completed its acquisition of NextWave Pharmaceuticals, Inc., a privately held, specialty pharmaceutical company focused on the development and commercialization of products for the treatment of attention deficit hyperactivity disorder (ADHD).

29 Nov 2012

Combination of mixed amphetamine salts and topiramate shows promise for cocaine dependence

Medication development efforts for cocaine dependence have yet to result in an FDA approved treatment. The powerful rewarding effects of cocaine, the profound disruptive impact of cocaine dependence on one's lifestyle, and the tendency of cocaine to attract people who make poor life choices and then exacerbate impulsive behavior all make cocaine a vexing clinical condition.

28 Nov 2012

Pfizer announces intention to acquire NextWave

Pfizer Inc. today announced its intention to acquire NextWave Pharmaceuticals, a privately held, specialty pharmaceutical company focused on the development and commercialization of unique products for the treatment of attention deficit/hyperactivity disorder (ADHD) and related central nervous system (CNS) disorders.

23 Oct 2012

Kids with ADHD tend to feel that they benefit from medications

Children living with attention deficit hyperactivity disorder (ADHD) tend to feel that they benefit from medication to treat the condition and do not feel that the medication turns them into 'robots', according to a report published today. In fact, they report feeling that medication helps them to control their behaviour and make better decisions.

19 Oct 2012

FTC votes to approve Watson's acquisition of Actavis

Watson Pharmaceuticals, Inc. today announced that the Federal Trade Commission (FTC) has voted to approve Watson's acquisition of the Actavis group of companies.

16 Oct 2012

ADHD drugs do not appear to have long-term effects on the brain

Drugs used to treat Attention Deficit Hyperactivity Disorder (ADHD) do not appear to have long-term effects on the brain, according to new animal research from Wake Forest Baptist Medical Center.

19 Jul 2012

Ampio announces advancement of NCE001 to preclinical development

Ampio Pharmaceuticals, Inc., a biopharmaceutical company developing repurposed drugs and new molecular entities (NMEs) that treat inflammatory diseases, including osteoarthritis, diabetic macular edema (DME) and sexual dysfunction and conducting clinical trials on its four lead drugs announced today the advancement of NCE001, from its proprietary methylphenidate derivatives family of compounds, to preclinical development for the treatment of glioblastoma multiforme, renal cell carcinoma and inflammatory breast cancer following the granting of multiple composition of matter and use patents in the USA, Canada, Europe and China.

17 Jul 2012

Methylphenidate ‘could relieve cancer depression’

The drug methylphenidate is well tolerated among advanced cancer patients and shows promise in alleviating depression in this group, report researchers from Spain.

28 Jun 2012

Targeting noradrenergic system combats gait freezing in Parkinson’s patients

Methylphenidate may be a useful treatment for patients with advanced Parkinson's disease receiving subthalamic nucleus stimulation who experience gait hypokinesia and freezing, show findings from a randomized trial.

14 Jun 2012

Pisgah receives USPTO Notice of Allowance for drug abuse solution

Pisgah Laboratories, Inc. received Notice of Allowance from the United States Patent and Trademark Office for its patent application entitled "Opioid Salts and Formulations Exhibiting Anti-Abuse and Anti-Dose Dumping Properties."

2 Jun 2012

Researchers develop new form of specially bred mouse that mimics ADHD

The number of attention deficit hyperactivity disorder (ADHD) cases in the United States are exploding. According to a 2011 statement by the Centers for Disease Control and Prevention, nearly one in 10 American children is diagnosed with the disorder.

11 May 2012

Ritalin use in ADHD rises four-fold over a decade

According to latest figures prescriptions for Ritalin for attention deficit hyperactivity disorder (ADHD) have quadrupled in a decade. This has raised concerns that it is being given to children at the expense of alternative treatments and without appreciation of long-term effects.

8 May 2012

Methylphenidate may help induce recovery from propofol anesthesia

The ability of the commonly used stimulant methylphenidate (Ritalin) to speed recovery from general anesthesia appears to apply both to the inhaled gas isoflurane, as previously reported, and to the intravenous drug propofol. Members of the same Massachusetts General Hospital (MGH) research team that reported the isoflurane study are publishing similar results for propofol in the May issue of Anesthesiology, and their paper has been issued online.

6 Apr 2012

Diagnostic inflation of ADHD

What experts and the public have already long suspected is now supported by representative data collected by researchers at Ruhr-Universit-t Bochum (RUB) and University of Basel: ADHD, attention deficit hyperactivity disorder, is over-diagnosed.

31 Mar 2012

Methylphenidate may affect learning and memory in children with ADHD

New research with monkeys sheds light on how the drug methylphenidate may affect learning and memory in children with attention deficit hyperactivity disorder.

11 Mar 2012

Shire to commence two Vyvanse and Concerta Phase 4 comparison trials for ADHD

As part of its continued commitment to ADHD research, Shire plc, the global specialty biopharmaceutical company, today announced it is initiating two Phase 4 clinical trials to compare Vyvanse (lisdexamfetamine dimesylate) Capsules, (CII) to Concerta (methylphenidate HCl) Extended-Release Tablets.

7 Mar 2012

Young children more likely to be diagnosed and treated for ADHD

The youngest children in the classroom are significantly more likely to be diagnosed with attention-deficit/hyperactivity disorder (ADHD) - and prescribed medication - than their peers in the same grade, according to a study just published in CMAJ.

6 Mar 2012

Single dose of Ritalin may raise awareness of mistakes: Study

The study, by Dr Rob Hester from the Department of Psychological Sciences and colleagues at the Queensland Brain Institute, investigated how the brain monitors ongoing behavior for performance errors – specifically failures of impulse control. This study found that a single dose of methylphenidate (Ritalin) results in significantly greater activity in the brain’s error monitoring network and improved volunteers’ awareness of their mistakes.

28 Feb 2012

Ritalin improves awareness of performance errors

People who take Ritalin are far more aware of their mistakes, a University of Melbourne study has found.

27 Feb 2012

Stimulants do not increase risk of cardiovascular events in youth with ADHD

Attention-deficit/hyperactivity disorder (ADHD) affects 5-9% of youth and is frequently treated with stimulant medications, such as methylphenidate and amphetamine products. A recent safety communication from the US Food and Drug Administration advised that all patients undergoing ADHD treatment be monitored for changes in heart rate or blood pressure.

9 Feb 2012